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1. Introduction
Viral hepatitis is a family of viral infections that affect the liver caused by at least five distinct
viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D
virus (HDV), and hepatitis E virus (HEV). Hepatitis A and E appear as acute self-limiting diseases
and do not become chronic; occasionally, a fulminant form of hepatitis develops (acute liver
failure), which can lead to death. In contrast, HBV and HCV infections can evolve as serious
chronic diseases that often remain clinically silent for decades. Fulminant hepatitis B develops
in 0.1–0.6% of acute cases; rarely, it also have been reported among perinatally infected infants.
People with chronic hepatitis B and C are infectious to others [1, 2, 3]. HDV is a "defective virus"
that requires co-infection with HBV for its own replication. Infection with HDV is associated
with the most severe forms of acute and chronic hepatitis in many HBsAg-positive patients [4].
Subjects affected by chronic HBV and/or HCV infection are at increased risk for liver cirrhosis
and hepatocellular carcinoma (HCC) later in life. About 5% of all acute HBV infections prog‐
ress to chronic active infection (persistence of HBsAg for more than 6 months). The risk of
developing a chronic hepatitis B decreases with age of infection [5], dropping from 90% in infants
< 1 years old to 30%-50% in children 1-5 years old and to 5%-10% in adults [1, 6, 7]. Chronic active
hepatitis B develops in more than 25% of carriers and often results in cirrhosis; approximately
the same proportion of cases dies prematurely from cirrhosis or liver cancer [5]. About 75%-85%
of subjects affected by HCV develop a chronic infection, 5%-20% develop cirrhosis and 1%-5%
die for cirrhosis or liver cancer [8].
2. Burden of HBV infection
Diseases caused by hepatitis B virus have a worldwide distribution. About one third of the
world’s population has been exposed to HBV with more than 2 billion people infected
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worldwide. Approximately 350 million subjects develop a chronic form and about 600,000 die
every year for acute or chronic consequences of hepatitis B [6, 9, 10].
The prevalence of HBV infection varies all around the world. In Western countries, it is
relatively rare and acquired primarily in adulthood with a prevalence of HBsAg positive <2%
(low endemicity areas). In Asia and most of Africa, HBV infection is common and usually
acquired perinatally or in childhood with a prevalence of HBsAg positive 2%-7% in inter‐
mediate endemicity areas and ≥8% in high endemicity areas [9, 11].
A general decrease of new cases of acute disease was observed in North America in the last
decades. Between 1987 and 2004 in the United States, the incidence declined 80%, falling from
10.7 per 100,000 (25,916 cases reported) to 2.1 per 100,000 (6,212 cases reported) in all age
groups, and the largest proportional decrease among 0-15 years (-95%) and 15-24 years (-87%)
[12]. In 2009, 3,371 new cases were reported to Centre for Diseases Control and Prevention
(CDC). Prevalence of HBsAg-positive individuals – chronic infection was generally low (0.33%
in 1976-1980, 0.42% in 1988-1994 and 0.30% in 2005-2006). Between 2004 and 2009, 800,000 to
1.4 million persons developed a chronic Hepatitis B, with about 3,000 deaths / year [12,13].
In the European Union, 7,000-8,000 newly diagnosed cases of hepatitis B occurr each year. The
incidence per 100,000 population has declined over the past ten years from 6.7 cases per 100,000
in 1995 to 1.5 cases per 100,000 in 2007. The prevalence of HBsAg-positives in the general
population of European countries reported from ECDC – European Centre for Disease Preven‐
tion and Control range from 0.1% to 7%. The higher rates are registered in the southern Europe,
being Romania the country with the highest prevalence (>4%), followed by medium preva‐
lence countries (> 1-2%) as Spain, Italy, and Greece. Belgium, Czech Republic, Finland, Germa‐
ny, Ireland, Netherlands, Slovakia and Sweden reported the lowest prevalence (<1%) [2,14].
Among developing areas, the highest prevalence are described in sub-Saharan regions of
Africa (≥10%) [15]. In 2005, North Africa and the Middle Eastern region showed lower
intermediate HBsAg endemicity across all age groups [16]. China and other countries of East
Asia are at high/intermediate endemicity for Hepatitis B. Most people in those regions become
infected during childhood and up-to 8–10% of the adult population is chronically infected.
There, liver cancer caused by chronic hepatitis B is among the first three causes of death from
cancer in men and a major cause of cancer in women [6]. Central Asia and the Caucasus are at
intermediate HBsAg endemicity too, with 2–5% of the general population chronically infected
by HBV. High HBV prevalence is reported also in the Amazon area (South America), in the
north regions of Canada and in Greenland [17].
3. Burden of HCV infection
Every year, 3-4 million people in the world are newly infected with the hepatitis C virus [8].
WHO estimates that approximately 3% (170 million persons) of the world’s population has
been infected with HCV [18] and about 150 million are chronically infected and at risk of
developing liver cirrhosis and/or liver cancer. More than 350,000 people die from related liver
diseases every year [8].
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The prevalence of  HCV infection is  higher (up to 15%) in some countries in Africa and
Asia. Countries with higher rates of chronic infection are Egypt (15%), Pakistan (4.8%) and
China (3.2%).
For most developed countries, the prevalence of HCV infection is <3%.
In the United States, the more recent estimates amount to 17,000 new Hepatitis C virus
infections and 2.7-3.9 million chronic infections (prevalence: 1.3%-1.9%) [13, 19]. With an HCV
antibody prevalence of 3.25%, persons born during 1945–1965 account for approximately three
fourths of all chronic HCV infections among adults [20].
In the European Union, hepatitis C showed a significant increase over the past ten years. The
number of newly reported cases incidence raised from 4.3 per 100,000 population in 1995 to
6.9 cases per 100,000 in 2007 (27,000-29,000 newly diagnoses /year). This trend may reflect
changes in testing practices and reporting rather than a real increase [14]. The highest preva‐
lence rates (more than 2%) are reported in the southern Europe countries, including Italy,
Romania and Spain. Medium prevalence was observed in Bulgaria, France, Greece, and
Poland. Countries with low prevalence (less than 1%) include Belgium, Germany, the Neth‐
erlands, Sweden, and the United Kingdom [14].
4. Cirrhosis and hepatocellular carcinoma attributable to HBV or HCV
With more than 5% of all cancers worldwide, hepatocellular carcinoma is one of the most
common malignant tumors. More than 500,000 cases are estimated every year [21], with a mean
annual incidence of around 3-4% [22]. In 2008, WHO estimated that cirrhosis and primary liver
cancer caused 849,000 and 695,000 deaths, respectively. These conditions, together, account
for approximately one of every forty deaths (2.7%) worldwide [23].
HBV and HCV chronic infection represents the main cause of cirrhosis and is the major
contributor to HCC in many parts of the world. Alcohol abuse is a critical risk factor for these
diseases, with some evidence for a synergistic effect in the presence of viral infection [24, 25].
The annual risk of HBV-related HCC is 0.5% for asymptomatic HBsAg carriers and 0.8% for
chronic hepatitis B cases [26]. Patients with related-HBV cirrhosis present a risk of developing
HCC 1,000 times higher than HBsAg-negative controls [27]. The HBV replication status may
play an important role in the development of HCC [28-30]. The relative risk of HCC among
HBsAg positive subjects could be about ten times higher than those without HBsAg, with
approximately a sixty-fold increase in the risk when they are positive for both HBsAg and
HBeAg [29].
Whereas liver cancer represents a rare occurrence during the first 10–15 years after HCV-
infection [31-35], the risk of HCC increases with the establishment of cirrhosis (yearly incidence
between 3–8%) [36-41]. The risk of cirrhosis is <10% in women infected at a young age and
>30% in men infected after the age of 40 over a 20 year period [42,43]. Genotype 1b, the most
prevalent in Europe and in Japan, could be associated with a higher incidence of HCC than
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other genotypes [44,45]. Co-infection of both HBV and HCV has been found in more severe
liver diseases than either infection alone [46].
The incidence of HCC reflects the global distribution of HBV and HCV infections with
approximately 80% of HCC cases occurring in developing countries. Eastern Asia, Middle
Africa and some Western African countries show age-adjusted incidence rates (AAIR) of
27.6-36.6 per 100,000 (in men), 20.8–31.1 per 100,000 and 30–48 per 100,000, respectively.
Northern Europe, Australia, New Zealand and the Caucasian populations of North and Latin
America (AAIR 1.5–3.0) represent the areas at lowest risk. The AAIR raises to about 10 per
100,000 in men in Southern Europe [47].
In a study published in 2006, Perz et al. estimated that, globally, 57% of cirrhosis cases were
attributable to either HBV (30%, ranging from 5% in North America to 57% in WHO Western
Pacific Region B) or HCV (27%, ranging from 16% in WHO Africa Regions D/E to 62% in
Western Pacific Region A). About three-quarters (78%) of HCC were attributable to HBV (53%)
or HCV (25%). The attributable fractions of HCC due to HBV or HCV ranged from 16% in
North America to 65% in Western Pacific Region B (China, Cambodia, etc.), and from 13% in
Eastern Mediterranean Region (Bahrain, Cyprus, Iran, Jordan, etc.) to 66% in Western Pacific
Region A, respectively. The two viruses taken together accounted for >50% of HCC in all of
the regions and for >50% of cirrhosis in 8 of 11 regions [48].
5. Risk factors for hepatitis B and C
HBV is transmitted by percutaneous or mucous membrane contact with infected blood or other
body fluids of an infected person.
In developing countries the transmission routes are perinatal, early childhood exposure,
unsafe injections or needle stick in health care settings, unsafe blood transfusions, unprotected
sexual contact [6].
In developed countries infections are mainly transmitted during young adulthood by sexual
activity and injecting drug use. Historically, male homosexual contacts have been associated
with an high risk for HBV infection [6]. More recently, heterosexual transmission is recognised
as the most common cause of acute HBV infection in adults [12]. The risk of sexual transmission
is mostly related with multiple sex partners and history of a sexually transmitted infections [7].
In some countries, transmission via household contacts (persons who have prolonged but non
sexual interpersonal contacts with someone), has also been demonstrated [1, 6]. Sharing items
such as razors or toothbrushes with an infected person also give rises to HBV transmission [10].
HBV is a common cause of occupational disease transmitted from patients to health care
workers and also to health care workers’ families. The risk of transmission depends on the
viral load and exposure frequency but the most important factors in the exposure are health
care workers skill levels and expertise and the specific hospital departments environment (e.g.,
dentists, dental hygienists, emergency medical technicians, first responders, laboratory
technologists/technicians, nurses, nurse practitioners, phlebotomists, physicians, physician
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assistants, and students entering these professions). In contrast, transmission from health care
workers to patients is rare [49]. Dentists and dental staff are the category at the highest risk of
infection and transmission of HBV to their patients [50].
Several studies showed that tattooing, acupuncture and beauty treatments are associated with
hepatitis B transmission when sterilization or disinfection procedures are unavailable [51-53].
In many contexts, the risk of HBV transmission via transfusion of blood and plasma-derived
products has been eliminated through donor screening but in some developing countries it
can continue to occur in heath care settings by not-adherence to guidelines [12].
Travellers to developing countries with high rates of hepatitis B are considered at high risk,
especially subjects who engage in unprotected sex with local commercial sex workers [6, 54].
HCV is a blood borne pathogen, most commonly transmitted through exposure to infectious
blood [8].
In the past, blood transfusion represented one of the most serious risk factor for HCV infection.
In the late 1980s and early 1990s, specific donor screening for HCV was implemented and the
risk of HCV infection from a unit of transfused blood was drastically reduced. As of 2001, the
risk is less than one per million transfused blood units [55]. Currently, in Europe, the estimated
residual risk for acquiring HCV via blood products ranges from 1 to 40 per 10 million trans‐
fusions [7].
Nosocomial transmission of HCV via contaminated substances or multiple dose vials as well
as via haemodialysis, is still a concern [7]. Especially in developing countries, the incidence of
hepatitis C virus infection among patients on hemodialysis was significantly higher [56].
Although in many developing countries unsafe medical injections and transfusions are still
predominant sources of infection, at global level HCV transmission is increasingly driven by
injected drugs use [57]. In 2010, about 10.0 million injection drug users (IDUs, range 6.0–15.2
million) could have been anti-HCV positive with a midpoint prevalence of 67.0% among all
IDUs globally [58]. Individuals who injected drugs, even if they did so on occasionally in the
past, are at highest risk for HCV infection that is rapidly acquired following the initiation of
injection drug use and occurs from the sharing of needles, syringes, or other equipment
associated with drug use [55]. Increasing age, increasing duration of injecting drug use and
imprisonment were identified as risk factors [2, 59, 60].
Less commonly, hepatitis C may be transmitted through sex with an infected person. In 2001,
sexual exposures accounted for about 15% of cases of hepatitis C in USA [55]. High-risk sexual
behaviour among men who have sex with men (predominantly HIV-positive) may predispose
to HCV infection probably via permucosal route and mucosal damage rather than by sexual
contact [7].
Together with HBV, HCV is considered a common cause of occupational hazard for health
care workers, significantly correlated with factors such as the type of procedure (replacing a
hollow-bore needle in a patient's vein or artery, needle recapping, the use of sharp, etc), the
severity of percutaneous injury, the gender of the personnel, expertise levels and hospital
wards [49].
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Other parenteral exposures such as body piercing and tattooing in potentially nonsterile
settings [61], or being born to a hepatitis C infected mother [8] have to be considered important
risk factors for HCV transmission. Nevertheless, in 2001 CDC estimated that in USA about
10% of people with HCV infection have no recognized source for their infection [55].
6. Prevention of hepatitis B and C
The hepatitis B vaccine, the first vaccine against a major human cancer, is the milestone in
hepatitis B prevention [6].
A plasma-derived vaccine was licensed in the early 1980s. It derived from HBsAg particles
purified from the plasma of chronic patients. The vaccine was safe and effective but not well
accepted because of fears of transmission of live HBV and other bloodborne pathogens, such
as HIV [5].
Since the mid 1980s, a new recombinant hepatitis B vaccine has gradually replaced the plasma-
derived vaccine. HBsAg in the vaccine is produced in yeast or mammalian cells into which the
HBsAg gene or HBsAg/pre-HBsAg genes are inserted using plasmids [9].
The vaccine has an outstanding record of safety and results really effective in preventing
infection and its chronic consequences [6, 7]. After three intramuscular doses, more than 95%
of infants, children, and adolescents (0-19 years) and more than 90% of healthy adults develop
adequate antibody responses. By 60 years of age, 75% of immunised subjects develop protec‐
tive antibody titers.
Hepatitis B vaccine is available as monovalent formulations or in combination with diphthe‐
ria–tetanus–pertussis, Haemophilus influenzae type b, hepatitis A and inactivated polio
vaccines [9].
The recommended doses vary with the different formulations of vaccine and the age of the
vaccinees. From 2 to 4 times the normal adult dose or an increased number of doses may be
necessary in hemodialysis patients or in other immunocompromised subjects to induce
protective antibodies [5]. A recombinant vaccine using alum and lipid A as adjuvants is
available for adult patients with renal insufficiency [62].
Conventionally, the primary hepatitis B immunization infancy series consists of 3 doses; 4
doses may be administered for programmatic reasons according to the schedules of national
routine immunization programmes. For older children and adults, the primary series of 3 doses
with appropriate intervals applies [9]. The use of routine booster doses does not appear
necessary to maintain long-term protection in successfully vaccinated immunocompetent
children [9, 63, 64].
Although some studies suggest that a universal infant vaccination may be more cost-effective
in intermediate- and high-endemicity regions, WHO strongly recommends that all newborn
infants receive the hepatitis B vaccine at birth [7, 9, 65-69, 75]. Universal immunization
beginning at birth and other successful hepatitis B vaccination strategies have drastically
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reduced HBV transmission in many high endemicity countries. In recent years, the signifi‐
cantly reduced price of hepatitis B vaccine in developing countries has facilitated its intro‐
duction into many more countries [6, 9]. As of 2011, 179 countries had incoporated hepatitis B
vaccine as a part of their national infant immunization schedules, and an estimated 69% of the
2008 birth cohort received 3 doses of hepatitis B vaccine [6]. In 2006, approximately 27% of
newborns worldwide received a birth dose of hepatitis B vaccine [70].
In areas where HBV is mainly spread from mother to infant at birth, the first dose of vaccine
should be given as soon as possible after birth, preferably within 24 hours. The need for catch-
up vaccination in cohorts of children with low coverage should be considered to increase the
number of protected children since the risk for chronic infection is highest in younger age
groups [9].
In intermediate/low endemicity countries target groups for catch-up vaccination can include
adolescents and people with risk factors for acquiring HBV infection, such as subjects fre‐
quently requiring blood or blood products, dialysis patients, people with chronic liver disease,
recipients of solid organ transplantations, people interned in prisons, injecting drug users,
household and sexual contacts of people with chronic HBV infection, people with multiple
sexual partners, men who have sexual contact with other men, HIV positives [7, 71, 76]. Health-
care workers, staff of facilities for developmentally disabled persons and others subjects
exposed to blood and blood products must be vaccinated. Immunization remains the best
defence not only for the workers themselves, but also to prevent transmission of infectious
agents to the their patients [9, 76]. Also unvaccinated or incompletely vaccinated travellers to
high endemicity countries should be offered the vaccine before leaving for endemic areas [6].
Prevaccination serological tests are not recommended routinely. Though routine postvacci‐
nation testing for immunity is not necessary, it is recommended 1-2 months after the last dose
of the vaccine series for high-risk individuals, such as people at risk of occupationally acquired
infection, infants born to HBsAg-positive mothers, chronic haemodialysis patients, HIV
positives and other immunocompromised people, sex partners or needle-sharing partners of
HBsAg positive subjects [9].
In several European countries and in USA, routine prenatal screening of pregnant women
for HBsAg to identify newborns who require postexposure immunoprophylaxis has been
introduced or recommended [2,  75]  and some developing countries  are considering this
opportunity  in  order  to  prevent  perinatal  hepatitis  B  virus  infection  [72-74].  In  some
European countries,  screening programmes for  high-risk groups (inject  drug users,  men
having sex with men, contacts of HBsAg-positive individuals,  health care workers) have
also been carried out [2].
Temporary immunity (3-6 months) may be obtained by administering hepatitis B immuno‐
globulin (HBIG) for postexposure prophylaxis [9].  HBIG is prepared from the plasma of
donors  with  high concentrations  of  anti-HBs.  The plasma is  screened to  eliminate  posi‐
tives for HBsAg, antibodies to HIV and hepatitis  C virus,  and HCV RNA [75].  HBIG is
typically used as an adjunct to hepatitis B vaccine for postexposure immunoprophylaxis
or  as  the  primary  means  of  protection  after  an  HBV  exposure  for  non-responders  to
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hepatitis B vaccination [75]. HBIG prophylaxis in conjunction with HBV vaccination may
be of additional benefit for infants born to HBsAg-positive mothers, particularly if they are
HBeAg positive, subjects exposed to HBsAg-positive blood or body fluids, people sexual‐
ly exposed to an HBsAg-positive person,  and patients  who need protection from recur‐
rent HBV infection following liver transplantation [9].
A vaccine against HCV is not yet available [8, 77], and immunoglobulin does not provide
protection [18]. The primary prevention is aimed to reduce the risk for HCV transmission [78]
and includes:
• avoiding unnecessary and unsafe injections, unsafe sharps waste collection and disposal;
• screening of blood, plasma, organ, tissue, and semen donors;
• controlling use of illicit drugs and preventing the sharing of injection equipment among
drug users;
• promoting protected sex with hepatitis C-infected subjects;
• advising household contacts of HCV infects about the risk related to share of sharp personal
items;
• avoiding tattoos,  piercings  and acupuncture  performed with not  sterilized equipment
[8,  79-81].
Identifying persons at risk but not yet infected with HCV provides opportunity for counseling
on how to reduce their risk [78].
Travelers should be advised against the use of medical, surgical, and dental equipments not
adequately sterilized or disinfected and they should consider the risks about getting a tattoo
or body piercing in areas where adequate sterilization or disinfection procedures might not be
available or practiced [18].
Secondary prevention aims to reduce risks for liver chronic diseases in HCV-infected persons
by identification, counseling, and testing and by providing appropriate medical management
and antiviral therapy [78, 82].
The determination of which risk groups to recommend for routine testing should be based on
the knowledge of the epidemiologic link between a risk factor and acquiring HCV infection,
prevalence of risk factors or behavior for infection in the population, and prevalence of
infection among those with a risk factors or behavior [78].
Risk groups to test routinely shoud be injected illegal drugs users; subjects who received (i)
clotting factor concentrates produced before the late 1980s, (ii) blood from a donor who later
tested positive for HCV infection, (iii) transfusion of blood / blood components or an organ
transplant before the early 1990s; patients on long-term hemodialysis or with persistently
abnormal alanine aminotransferase levels [78, 83].
Based on a recognized exposure, healthcare, emergency medical and public safety workers
after needle sticks, sharps, or mucosal exposures to HCV-positive blood and children born to
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HCV-positive mothers should be tested routinely. Immunoglobulin and antiviral agents are
not recommended for postexposure prophylaxis of hepatitis C.
In USA, CDC strongly recommends that adults of all ages at risk for HCV infection should be
tested; particularly, those born during 1945–1965 without prior ascertainment of HCV risk
should receive one-time testing for HCV [20].
Counselling directed to HCV positives must include messages on how to protect the liver from
further harm by receiving hepatitis A and B vaccination if susceptible, reducing alcohol
consumption, avoiding new medicines (including over-the-counter and herbal agents)
without first checking with their health-care provider, and obtaining HIV risk testing [20].
Persons overweight/obese must loose weight and follow an healthy diet and a physically active
health-style [20, 84].
First of all, HCV positives must not donate blood, tissue, or semen and/or share devices that
come into contact with blood, such as toothbrushes, dental appliances, razors, and nail
clippers, to minimize the risk of transmission to others [20].
Epidemiological surveillance represents the mainstay in the prevention of viral hepatitis since
it provides the information for determining new infections and trends in incidence, changing
patterns of transmission and persons at highest risk for infection, and for evaluating effective‐
ness or missed opportunities for prevention [78].
In USA, each week, state and territorial health departments report cases of acute, symptomatic
viral hepatitis to CDC’s [1].
Most of European countries have a passive mandatory surveillance system for acute hepatitis
having clinicians as the main source of data, using an electronic format at the national level,
and collecting a similar set of basic data. Underreporting is common, but the exact extent is
unknown [8].
Chronic hepatitis B and C, although accounting for the greatest burden of disease, are not
reported by most states.
Serologic surveys carried out periodically can add information on geographical variations in
prevalence of infections, populations at high risk, trends, and prevention programs [78].
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